Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation

Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic Carcinoma

WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that data from its Phase 1 clinical trial evaluating MYB RNA degrader, REM-422, in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC), has been accepted for a late-breaking oral presentation in the Clinical Trials Plenary Session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place on October 22-26 at the Hynes Convention Center in Boston.

The presentation will highlight results from the ongoing Phase I trial’s primary objectives of defining safety, dose-limiting toxicities, and a recommended phase 2 dose (RP2D). Secondary objectives include evaluating preliminary antitumor activity and pharmacokinetics of REM-422 in patients with R/M ACC.

Oral Presentation Details:

• Title: A Phase I Trial of the MYB RNA degrader REM-422 in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)
• Presenter: Glenn J. Hanna, MD, Dana-Farber Cancer Institute
• Date & Time: Friday, October 24
  Plenary Session 4: Clinical Trials Plenary Session 10:00 -11:40 am
• Location: Level 3, Ballroom AB
  

Poster Presentation Details:

• Title: A phase I trial of the MYB RNA degrader REM-422 in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)
• Presenter: Glenn Hanna, MD, Dana-Farber Cancer Institute
• Session and Poster Number: Poster Session B, LB-B005
• Date and Time: Friday, October 24, 12:30-4pm
• Location: Level 2, Exhibit Hall D
  

Additionally, Remix Therapeutics will be taking part in a session on targeting RNA with small molecules.

Session Details:

• Title: Concurrent Session 9: Targeting RNA with Small Molecules
• Co-Chair: Chris Bowden, MD, Chief Medical Officer, Remix Therapeutics
• Presenter: Charles Kung, PhD, Vice President of Biology, Remix Therapeutics
• Title: REM-422, a first-in-class mRNA degrader of the MYB oncogene
• Date & Time: Saturday, October 25, 4:15 – 5:55 pm
• Location: Level C, Ballroom 3

About REM-422
REM-422 is a first/best-in-class, potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of poison exons in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in Phase 1 clinical studies in both ACC and Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). REM-422 was granted Orphan Drug Designation by the U.S Food and Drug Administration for ACC and AML.

About Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lisa Buffington
Buffington Comms
lbuffington@remixtx.com

Investor Contact:
Will O'Connor  
Precision AQ
Will.OConnor@precisionaq.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.